In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Amishi Y. Shah, MD
Advertisement
Articles by Amishi Y. Shah, MD
Advertisement
Latest Updated Articles
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerPublished: January 17th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up
2
FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs
3
Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer
4
FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications
5
